NAUT vs. SENS, QSI, FEIM, MASS, QTRX, PRE, RPID, OWLT, KEQU, and SEER
Should you be buying Nautilus Biotechnology stock or one of its competitors? The main competitors of Nautilus Biotechnology include Senseonics (SENS), Quantum-Si (QSI), Frequency Electronics (FEIM), 908 Devices (MASS), Quanterix (QTRX), Prenetics Global (PRE), Rapid Micro Biosystems (RPID), Owlet (OWLT), Kewaunee Scientific (KEQU), and Seer (SEER). These companies are all part of the "measuring and control equipment" industry.
Nautilus Biotechnology vs. Its Competitors
Nautilus Biotechnology (NASDAQ:NAUT) and Senseonics (NYSE:SENS) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their institutional ownership, dividends, earnings, risk, valuation, profitability, media sentiment and analyst recommendations.
50.7% of Nautilus Biotechnology shares are owned by institutional investors. Comparatively, 12.4% of Senseonics shares are owned by institutional investors. 41.1% of Nautilus Biotechnology shares are owned by insiders. Comparatively, 3.6% of Senseonics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.
Nautilus Biotechnology presently has a consensus price target of $2.13, indicating a potential upside of 93.18%. Senseonics has a consensus price target of $1.54, indicating a potential upside of 247.07%. Given Senseonics' stronger consensus rating and higher possible upside, analysts plainly believe Senseonics is more favorable than Nautilus Biotechnology.
Nautilus Biotechnology has a net margin of 0.00% compared to Senseonics' net margin of -362.30%. Nautilus Biotechnology's return on equity of -32.53% beat Senseonics' return on equity.
Senseonics has higher revenue and earnings than Nautilus Biotechnology. Senseonics is trading at a lower price-to-earnings ratio than Nautilus Biotechnology, indicating that it is currently the more affordable of the two stocks.
Nautilus Biotechnology has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Comparatively, Senseonics has a beta of 0.83, indicating that its stock price is 17% less volatile than the S&P 500.
In the previous week, Nautilus Biotechnology had 2 more articles in the media than Senseonics. MarketBeat recorded 3 mentions for Nautilus Biotechnology and 1 mentions for Senseonics. Nautilus Biotechnology's average media sentiment score of 0.90 beat Senseonics' score of -0.07 indicating that Nautilus Biotechnology is being referred to more favorably in the media.
Summary
Nautilus Biotechnology beats Senseonics on 9 of the 16 factors compared between the two stocks.
Get Nautilus Biotechnology News Delivered to You Automatically
Sign up to receive the latest news and ratings for NAUT and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding NAUT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Nautilus Biotechnology Competitors List
Related Companies and Tools
This page (NASDAQ:NAUT) was last updated on 10/15/2025 by MarketBeat.com Staff
